B-S.A.F.E.
Global, multi-center, post-market evaluation
-
1000 unique procedures
-
20 medical centers worldwide
-
Real-world comprehensive practice insights
-
Clinical utilization trends, experiences, and physician-reported outcomes
B-S.A.F.E. (Biopsy with SinglePass: Assessing Fast & Effective Tract Closure) will be one of the most comprehensive real-world data sets in the biopsy space to date.
The B-S.A.F.E. evaluation will assess:
-
Reduction in post-biopsy bleeding and complications
-
Reduction in post-biopsy observation time
-
Workflow optimization
"The SinglePass device represents a transformational advancement in the world of core needle biopsy. With the ability of SinglePass to provide immediate and reliable tract closure, we are already witnessing an inevitable shift in the way we manage bleeding risk and patient recovery. I'm proud to contribute to this evaluation and help drive the future standard of care.”
Dr. Alexander Misono, MD, MBA, RPVI
Chief of Interventional Radiology
Hoag Hospital Irvine, Irvine, CA
"I use Single Pass on every visceral biopsy for both tumor and parenchyma, including kidney and liver!” “This innovative device efficiently seals biopsy channels, significantly reducing bleeding risks and improving patient safety across all my biopsy procedures."
Dr. Frances Kang, MD
Clinical Chief of Interventional Radiology
Robert Wood Johnson University Hospital
New Brunswick, NJ